Realignment of Established Targets and Mechanisms for Delaying or Reversing T1D

The goal of this invitation is to accelerate therapy development by increasing the number of identified candidates for clinical interrogation in T1D through the realignment of targets and mechanisms under investigation in other fields or disease indications.

To expand target validation and preclinical research, a well-reasoned and methodological approach toward determining whether a target or mechanism is applicable to T1D is of great interest. In particular, the ability to rapidly translate current tools such as animal models, antibodies, assays, and other reagents for T1D-based discovery research represents an important opportunity for acceleration of the T1D clinical pipeline.

Funding: $750,000 total 

Duration: 3 years 

Research Authority due date: 14.8.22

LOI (required) due date: 23.8.22

Full proposal due date: 4.10.22